Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
2.780
-0.020 (-0.71%)
Aug 10, 2026, 11:32 AM EDT - Market open
Fate Therapeutics Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Fate Therapeutics stock has a consensus rating of "Buy" and an average price target of $5.41. The average 1-year stock price forecast is 94.60% higher than the current stock price, while the lowest is $2.20 (-20.86%) and the highest is $8.00 (+187.77%).
Price Target: $5.41 (+94.60%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Jul 9, 2026.
Analyst Ratings
The average analyst rating for Fate Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 6 | 6 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 11 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Jul 10, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $7 | Buy | Reiterates | $7 | +151.80% | Jul 9, 2026 |
Unknown Analyst Mizuho Securities No rating | Mizuho Securities | Buy Maintains $8 | Buy | Maintains | $8 | +187.77% | Jun 22, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $6 | Buy | Reiterates | $6 | +115.83% | Jun 9, 2026 |
| Bank of America Securities | Bank of America Securities | Hold Reiterates $2 → $2.2 | Hold | Reiterates | $2 → $2.2 | -20.86% | May 22, 2026 |
Financial Forecast
Revenue This Year
5.25M
from 6.65M
Decreased by -21.05%
Revenue Next Year
5.24M
from 5.25M
Decreased by -0.21%
EPS This Year
-1.04
from -1.15
EPS Next Year
-0.99
from -1.04
EPS and Forward PE are based on non-GAAP adjusted numbers.